TY - JOUR
T1 - Imaging assessment of bioresorbable vascular scaffolds
AU - Sotomi, Yohei
AU - Suwannasom, Pannipa
AU - Tenekecioglu, Erhan
AU - Collet, Carlos
AU - Nakatani, Shimpei
AU - Okamura, Takayuki
AU - Muramatsu, Takashi
AU - Ishibashi, Yuki
AU - Tateishi, Hiroki
AU - Miyazaki, Yosuke
AU - Asano, Taku
AU - Katagiri, Yuki
AU - von zur Muehlen, Constantin
AU - Tanabe, Kengo
AU - Kozuma, Ken
AU - Ozaki, Yukio
AU - Serruys, Patrick W.
AU - Onuma, Yoshinobu
N1 - Funding Information:
Conflict of interest Y. Sotomi received speaker honoraria from Abbott Vascular Japan and research grants from GOODMAN, Fukuda Memorial Foundation for Medical Research and SUNRISE lab. T. Muramatsu received speaker honoraria from Abbott Vascular Japan. K. Kozuma and K. Tanabe are members of Advisory Board of Abbott Vascular Japan, and receive honorarium for lecture from Abbott Vascular Japan. P. W. Serruys is a member of the Advisory Board for Abbott Vascular. Y. Onuma is a member of the Advisory Board for Abbott Vascular and received speaker honoraria from Terumo. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© 2017, Japanese Association of Cardiovascular Intervention and Therapeutics.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Vascular reparative therapy has become a reality with bioresorbable scaffolds (BRSs). To assess acute and long-term performance of the device, multimodality imaging would be essential. Radiopacity of metal hinders the imaging assessment, whereas radiolucent polymeric scaffolds allow for a precise imaging assessment with either invasive or non-invasive modality at baseline and at follow-up, which is one of the advantages of polymeric BRSs. Recent large trials evaluating clinical results of the first-generation BRS technology raised concerns about the safety and efficacy of these devices, namely, scaffold thrombosis. Intensive research with multimodality imaging in the field is being conducted to have in-depth understanding of the issues, which will facilitate the improvement of implantation techniques and the development of the next-generation BRSs. The current review focuses on the clinical application of the imaging modalities to assess the short- and long-term performance of the Absorb BVS.
AB - Vascular reparative therapy has become a reality with bioresorbable scaffolds (BRSs). To assess acute and long-term performance of the device, multimodality imaging would be essential. Radiopacity of metal hinders the imaging assessment, whereas radiolucent polymeric scaffolds allow for a precise imaging assessment with either invasive or non-invasive modality at baseline and at follow-up, which is one of the advantages of polymeric BRSs. Recent large trials evaluating clinical results of the first-generation BRS technology raised concerns about the safety and efficacy of these devices, namely, scaffold thrombosis. Intensive research with multimodality imaging in the field is being conducted to have in-depth understanding of the issues, which will facilitate the improvement of implantation techniques and the development of the next-generation BRSs. The current review focuses on the clinical application of the imaging modalities to assess the short- and long-term performance of the Absorb BVS.
UR - http://www.scopus.com/inward/record.url?scp=85040030161&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85040030161&partnerID=8YFLogxK
U2 - 10.1007/s12928-017-0486-5
DO - 10.1007/s12928-017-0486-5
M3 - Review article
C2 - 28766253
AN - SCOPUS:85040030161
SN - 1868-4300
VL - 33
SP - 11
EP - 22
JO - Cardiovascular Intervention and Therapeutics
JF - Cardiovascular Intervention and Therapeutics
IS - 1
ER -